The stock of BioVie Inc (BIVI) has gone up by 9.17% for the week, with a 11.21% rise in the past month and a 16.67% rise in the past quarter. The volatility ratio for the week is 3.75%, and the volatility levels for the past 30 days are 3.01% for BIVI. The simple moving average for the past 20 days is 11.21% for BIVI’s stock, with a -34.32% simple moving average for the past 200 days.
Is It Worth Investing in BioVie Inc (NASDAQ: BIVI) Right Now?
The stock has a 36-month beta value of 1.15. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BIVI is 16.15M, and at present, short sellers hold a 8.97% of that float. On June 13, 2025, the average trading volume of BIVI was 412.90K shares.
BIVI) stock’s latest price update
BioVie Inc (NASDAQ: BIVI) has experienced a rise in its stock price by 7.21 compared to its previous closing price of 1.11. However, the company has seen a gain of 9.17% in its stock price over the last five trading days. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC purchased a new position in shares of BioVie Inc. (NASDAQ:BIVI – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,213 shares of the company’s stock, valued at approximately $28,000. Squarepoint Ops LLC owned about 0.08% of BioVie at the end of the most recent reporting period. Other institutional investors and hedge funds have also modified their holdings of the company. NewEdge Advisors LLC lifted its stake in shares of BioVie by 14,000.0% during the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock valued at $28,000 after buying an additional 14,000 shares in the last quarter. Northern Trust Corp purchased a new position in shares of BioVie during the 4th quarter valued at $34,000. Two Sigma Investments LP purchased a new position in shares of BioVie during the 4th quarter valued at $57,000. Prosperity Wealth Management Inc. purchased a new position in shares of BioVie during the 4th quarter valued at $63,000. Finally, Bank of Montreal Can purchased a new position in shares of BioVie during the 4th quarter valued at $100,000. Hedge funds and other institutional investors own 4.59% of the company’s stock. BioVie Price Performance Shares of BIVI stock opened at $1.10 on Wednesday. The company has a market capitalization of $20.43 million, a P/E ratio of -0.11 and a beta of 0.77. The company’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.55. BioVie Inc. has a one year low of $0.62 and a one year high of $7.50. BioVie (NASDAQ:BIVI – Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.17. Analyst Upgrades and Downgrades Separately, Brookline Capital Management upgraded shares of BioVie to a “strong-buy” rating in a report on Tuesday, March 18th. Check Out Our Latest Stock Analysis on BioVie About BioVie (Free Report) BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Analysts’ Opinion of BIVI
Many brokerage firms have already submitted their reports for BIVI stocks, with Cantor Fitzgerald repeating the rating for BIVI by listing it as a “Overweight.” The predicted price for BIVI in the upcoming period, according to Cantor Fitzgerald is $7 based on the research report published on July 22, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see BIVI reach a price target of $47. The rating they have provided for BIVI stocks is “Buy” according to the report published on January 15th, 2021.
BIVI Trading at 21.55% from the 50-Day Moving Average
After a stumble in the market that brought BIVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.13% of loss for the given period.
Stock Fundamentals for BIVI
The total capital return value is set at -0.87. Equity return is now at value -93.23, with -67.31 for asset returns.
Based on BioVie Inc (BIVI), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -47.55. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -25.0.
Currently, EBITDA for the company is -31.95 million with net debt to EBITDA at 1.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.32.
Conclusion
To sum up, BioVie Inc (BIVI) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
